ClinicalTrials.gg
Sign In
Drug

Gallium-68 clinical trials

studies test it
54
open now
38
in phase 3
5
first study started
2010

How each study uses Gallium-68 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Gallium-68 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

[68Ga]Ga DOTA-5G
5
[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
3
[177Lu]Lu DOTA-ABM-5G
3
[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostic pair
3
[68Ga]Ga-OncoACP3
3

Development codes

AAA501
1

Studies by the year they started

54 studies that test it; most in 2024 (16)

Studies that test Gallium-68, by start year
YearStudies
20101
20161
20171
20181
20191
20201
20211
20221
20236
202416
202510
202614

By phase

A phase 1/2 study counts in both.

Early Phase 1
19
Phase 1
16
Phase 2
16
Phase 3
5
No phase
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Prostatic Neoplasms
8
Breast Neoplasms
6
Carcinoma, Renal Cell
3
Neoplasms
2
Urinary Bladder Neoplasms
2
Colorectal Neoplasms
2
Pancreatic Neoplasms
1
Carcinoma, Hepatocellular
1
Diabetes Mellitus, Type 2
1
Pituitary Neoplasms
1
Head and Neck Neoplasms
1
Hyperaldosteronism
1

Who runs them

Industry 17 · Other 37

University of California, Davis (4) · Philogen S.p.A. (4) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (4) · RenJi Hospital (4) · Peking University Cancer Hospital & Institute (3) · Novartis Pharmaceuticals (2) · Peking Union Medical College Hospital (2) · John O. Prior (2)

Often tested with

Tested in the same studies.

SAR425899 (1) · CM500 (1) · Lutetium-177 (1) · ALF-NOTA-FAPI-04 F-18 (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 15

Studies that test Gallium-68.

Studies

Open first, then newest update. How each study uses Gallium-68 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 54

See all 54 studies that test Gallium-68 →

Given beside what is tested · 10 — Gallium-68 is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 15, 2026.

Newly registered1

Codes

What other systems call Gallium-68 · ClinicalTrials.gg INT000637

  • MeSH (NLM) C000615430Gallium-68One source NLM
  • UNII (FDA) 98B30EPP5SGALLIUM GA-68Confirmed NLM, Wikidata
  • Wikidata Q2516934gallium-68Confirmed NLM, Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.